Evidence map›Paper›PMID 35115570›Full record

ArticleScientific reports2022

Simple, sensitive, specific self-sampling assay secures SARS-CoV-2 antibody signals in sero-prevalence and post-vaccine studies.

Maryam Khan, Carolina Rosadas, Ksenia Katsanovskaja, Isaac D Weber, Justin Shute, Samreen Ijaz, Federica Marchesin, Eleanor McClure, Salem Elias, Barnaby Flower and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Validation of the GSPVaccines · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Maryam KhanDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Carolina RosadasDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Ksenia KatsanovskajaDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Isaac D WeberDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Justin ShutePublic Health England, 61 Colindale Ave, London, NW9 5EQ, UK.ORCID 0000-0001-6455-5126
Samreen IjazPublic Health England, 61 Colindale Ave, London, NW9 5EQ, UK.
Federica MarchesinDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Eleanor McClureDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Salem EliasDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Barnaby FlowerDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
He GaoDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Rachael QuinlanDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Charlotte ShortDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.ORCID 0000-0002-4974-8824
Annachiara RosaFrancis Crick Institute, 1 Midland Rd, Somers Town, London, NW1 1AT, UK.ORCID 0000-0001-7433-6357
Chloe RoustanFrancis Crick Institute, 1 Midland Rd, Somers Town, London, NW1 1AT, UK.
Maya MosheDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Graham P TaylorDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Paul ElliottImperial College Healthcare NHS Trust, St Mary's Hospital, Praed St, Paddington, London, W2 1NY, UK.ORCID 0000-0002-7511-5684
Graham S CookeDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.ORCID 0000-0001-6475-5056
Peter CherepanovFrancis Crick Institute, 1 Midland Rd, Somers Town, London, NW1 1AT, UK.
Eleanor ParkerDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Myra O McClureDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK.
Richard S TedderDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, St Mary's Campus, Praed Street, London, W2 1NY, UK. r.tedder@imperial.ac.uk.
St Mary's Hospital · GBImperial College Healthcare NHS Trust · GBThe Francis Crick Institute · GBPublic Health England · GB

Funding

Medical Research Council MC_PC_19078Medical Research Council MR/R023484/1Medical Research Council MR/S019669/1Wellcome Trust FC001061
6 · The paper itself

Abstract

At-home sampling is key to large scale seroprevalence studies. Dried blood spot (DBS) self-sampling removes the need for medical personnel for specimen collection but facilitates specimen referral to an appropriately accredited laboratory for accurate sample analysis. To establish a highly sensitive and specific antibody assay that would facilitate self-sampling for prevalence and vaccine-response studies. Paired sera and DBS eluates collected from 439 sero-positive, 382 sero-negative individuals and DBS from 34 vaccine recipients were assayed by capture ELISAs for IgG and IgM antibody to SARS-CoV-2. IgG and IgM combined on DBS eluates achieved a diagnostic sensitivity of 97.9% (95%CI 96.6 to 99.3) and a specificity of 99.2% (95% CI 98.4 to 100) compared to serum, displaying limits of detection equivalent to 23 and 10 WHO IU/ml, respectively. A strong correlation (r = 0.81) was observed between serum and DBS reactivities. Reactivity remained stable with samples deliberately rendered inadequate, (p = 0.234) and when samples were accidentally damaged or 'invalid'. All vaccine recipients were sero-positive. This assay provides a secure method for self-sampling by DBS with a sensitivity comparable to serum. The feasibility of DBS testing in sero-prevalence studies and in monitoring post-vaccine responses was confirmed, offering a robust and reliable tool for serological monitoring at a population level.

Indexed as

Antibodies, ViralBiomarkersCOVID-19COVID-19 TestingCOVID-19 VaccinesDried Blood Spot TestingFeasibility StudiesFemaleHumansImmunoglobulin GImmunoglobulin MMaleSARS-CoV-2Sensitivity and SpecificitySeroepidemiologic StudiesSpecimen HandlingAntibodies, ViralBiomarkersCOVID-19 VaccinesImmunoglobulin GImmunoglobulin M

Identifiers

PMID35115570
PMCPMC8814240
OpenAlexW4210249010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.